Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum MedMira Inc MMIRF


Primary Symbol: V.MIR

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely... see more

TSXV:MIR - Post Discussion

MedMira Inc > Optimism
View:
Post by Torqueyturkey on Jul 12, 2021 6:30pm

Optimism

... Elsewhere... This taken from the MIR.V discussion board on yahoo financial "...MedMira has utilized its patented Rapid Vertical Flow (RVF) technology and developed the companys first rapid antigen test, VYRA CoV-2 Antigen Test (VYRA CoV-2), designed to detect SARS-CoV-2 virus in the swab samples. VYRA CoV-2 product expands the existing COVID-19 product family and directly addresses the wishes of our customers for an equally fast, reliable, and easy-to-use testing solution. VYRA CoV-2 saliva-based swab test is designed to be non-invasive and user-friendly, making this test more suitable for the home settings. The successful development of this test opens up a new product line that has been a pioneering step for MedMira, said Hermes Chan, CEO of MedMira. With this we offer customers our COVID-19 product bundle that can accommodate various testing needs. For example, the VYRA CoV-2 can used to determine if the person is infected; REVEALCOVID-19 PLUS [PLUS] tells if anti-SARS-CoV-2 antibodies are present; and our REVEALCOVID-19 Nab-Y [Nab-Y] neutralizing test can potentially identify if the individual is immune to the virus..." Another poster remarked that the million sold volume today is a million bought... We don't know all that is going on. Every good card player knows not to show their cards too soon... ... If ever... Sounds like HC et al have used the recent uptick in prosperity to add depth to their product line. Keep in mind, the market loves acquisitions... .. And MIR makes for a great acquisition target. The top return will be on a full slate of approved product.. Time will tell..
Comment by august202013 on Jul 12, 2021 7:16pm
While is good to reach for the sky and be optimistic NOW must put feet on ground. Let's THINK for just a minute. What million being SOLD today without USA FDA APPROVAL ! MIR did withdraw their EUA for the COVID19 TEST KIT when the ONES with the PLUS submitted. Where were that MILLION sold ? Today with SKYPE or FACETIME is free to confirm with Any country where item being SOLD. To TRY to ...more  
Comment by Torqueyturkey on Jul 13, 2021 12:31am
Ummmmmm...... I think the reference to "million sold" nasty have been related to the 1.27 million shares that traded today... Possibly written earlier in the day when just over a million had sold, meaning someone else chose to buy those million shares... Value is in the eye of the beholder...
Comment by Torrequebrada on Jul 13, 2021 5:20am
there where 4 Mi. plus shares traded yesterday. ATS , TSX.V and 7 other trading sites
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities